Crinetics Pharmaceuticals Stock Forecast
Recent Crinetics Pharmaceuticals Stock Price | Crinetics Pharmaceuticals Stock Forecast Price | |
$46.81 | +20.79% |
$56.54 |
Recent Crinetics Pharmaceuticals Analyst Ratings Breakdown | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 12 | 11 | 11 | 10 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 1 | 1 | 1 | 1 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 1.15 | 1.17 | 1.17 | 1.18 |
The presented Crinetics Pharmaceuticals stock forecast (traded under symbol CRNX), for forward-twelve-months price target as shown at the top of this page, gives you the average Crinetics Pharmaceuticals stock forecast for forward target price for symbol CRNX, across the 13 analysts covering Crinetics Pharmaceuticals (CRNX), as reported in data provided by Zacks Investment Research via Quandl.com.
Investors should also take note that the median Crinetics Pharmaceuticals stock forecast price target (i.e. representing the middle ground number where half of analysts had a higher Crinetics Pharmaceuticals stock forecast and half had a lower Crinetics Pharmaceuticals stock forecast) was $55.0 as of 2024-03-29 (which is a different mathematical metric versus taking the average or mean), while the
highest Crinetics Pharmaceuticals stock forecast in the analyst group was $80.0, and the lowest Crinetics Pharmaceuticals stock forecast in the analyst group was
$40.0, with a standard deviation of $10.485. Get the latest Zacks research report on CRNX — FREE
Top Analyst Picks of the Dow
The Top 20 Largest U.S. Stocks By Market Cap
|
Free CRNX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (3.85 out of 4) 74th percentile
(ranked higher than approx. 74% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |